Abstract
Purpose of research: Revision of the literature on targeted therapy-induced diarrhea (TT-ID). Principal results: TT-ID is frequent; the mechanisms are mainly secretive, followed by ischemic or autoimmune ones. The duration of TT-ID is protracted over time. Its intensity is of grade G1-G3 but may be fatal in patients with diffuse colitis or on ipilimumab. However, no specific guidelines are available on management of different grades of TT-ID. Preventive measures with antibiotics, probiotics or activated charcoal should be further investigated. Loperamide is the first choice drug followed by octreotide. The role of corticosteroids is controversial. Conclusion: Early assessment and management of TT-ID is essential to prevent the worsening of this side-effect, patients' hospitalization and dose reduction or oncological treatment discontinuation. Future research is needed to better understand the pathophysiological mechanisms of TT-ID and it should also be investigated whether a specific pharmacological and/or non pharmachological approach is indicated.
| Original language | English |
|---|---|
| Pages (from-to) | 165-179 |
| Number of pages | 15 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 90 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Assessment
- Diarrhea
- Incidence
- Targeted therapy
- Treatment
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
- Medicine(all)
Cite this
Targeted therapy-induced diarrhea : A review of the literature. / Pessi, M. A.; Zilembo, N.; Haspinger, E. R.; Molino, L.; Di Cosimo, S.; Garassino, M.; Ripamonti, C. I.
In: Critical Reviews in Oncology/Hematology, Vol. 90, No. 2, 2014, p. 165-179.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeted therapy-induced diarrhea
T2 - A review of the literature
AU - Pessi, M. A.
AU - Zilembo, N.
AU - Haspinger, E. R.
AU - Molino, L.
AU - Di Cosimo, S.
AU - Garassino, M.
AU - Ripamonti, C. I.
PY - 2014
Y1 - 2014
N2 - Purpose of research: Revision of the literature on targeted therapy-induced diarrhea (TT-ID). Principal results: TT-ID is frequent; the mechanisms are mainly secretive, followed by ischemic or autoimmune ones. The duration of TT-ID is protracted over time. Its intensity is of grade G1-G3 but may be fatal in patients with diffuse colitis or on ipilimumab. However, no specific guidelines are available on management of different grades of TT-ID. Preventive measures with antibiotics, probiotics or activated charcoal should be further investigated. Loperamide is the first choice drug followed by octreotide. The role of corticosteroids is controversial. Conclusion: Early assessment and management of TT-ID is essential to prevent the worsening of this side-effect, patients' hospitalization and dose reduction or oncological treatment discontinuation. Future research is needed to better understand the pathophysiological mechanisms of TT-ID and it should also be investigated whether a specific pharmacological and/or non pharmachological approach is indicated.
AB - Purpose of research: Revision of the literature on targeted therapy-induced diarrhea (TT-ID). Principal results: TT-ID is frequent; the mechanisms are mainly secretive, followed by ischemic or autoimmune ones. The duration of TT-ID is protracted over time. Its intensity is of grade G1-G3 but may be fatal in patients with diffuse colitis or on ipilimumab. However, no specific guidelines are available on management of different grades of TT-ID. Preventive measures with antibiotics, probiotics or activated charcoal should be further investigated. Loperamide is the first choice drug followed by octreotide. The role of corticosteroids is controversial. Conclusion: Early assessment and management of TT-ID is essential to prevent the worsening of this side-effect, patients' hospitalization and dose reduction or oncological treatment discontinuation. Future research is needed to better understand the pathophysiological mechanisms of TT-ID and it should also be investigated whether a specific pharmacological and/or non pharmachological approach is indicated.
KW - Assessment
KW - Diarrhea
KW - Incidence
KW - Targeted therapy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84897574426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897574426&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2013.11.008
DO - 10.1016/j.critrevonc.2013.11.008
M3 - Article
C2 - 24373918
AN - SCOPUS:84897574426
VL - 90
SP - 165
EP - 179
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 2
ER -